Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

G1 Therapeutics stock

GTHX
US3621LQ1099
A2DR0J

Price

7.15
Today +/-
+0
Today %
+0 %

G1 Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the G1 Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the G1 Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the G1 Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze G1 Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

G1 Therapeutics Stock Price History

DateG1 Therapeutics Price
9/18/20247.15 undefined
9/16/20247.15 undefined

G1 Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into G1 Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by G1 Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects G1 Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of G1 Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into G1 Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing G1 Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on G1 Therapeutics’s growth potential.

G1 Therapeutics Revenue, EBIT and net profit per share

DateG1 Therapeutics RevenueG1 Therapeutics EBITG1 Therapeutics Net Income
2029e217.21 M undefined72.45 M undefined44.94 M undefined
2028e169.54 M undefined28.28 M undefined26.37 M undefined
2027e135.7 M undefined4.94 M undefined11.84 M undefined
2026e110.55 M undefined190.15 M undefined11.84 M undefined
2025e96.38 M undefined-11.61 M undefined2.83 M undefined
2024e75.01 M undefined-25.14 M undefined-22.2 M undefined
202382.51 M undefined-39.53 M undefined-47.97 M undefined
202251.3 M undefined-136.18 M undefined-147.56 M undefined
202131.48 M undefined-142.46 M undefined-148.35 M undefined
202045.29 M undefined-96.48 M undefined-99.25 M undefined
20190 undefined-129.04 M undefined-122.45 M undefined
20180 undefined-89.29 M undefined-85.29 M undefined
20170 undefined-60.97 M undefined-64.88 M undefined
20160 undefined-30.39 M undefined-34.7 M undefined
2015520,000 undefined-15.42 M undefined-21.69 M undefined
20141.04 M undefined-6.68 M undefined-7.18 M undefined

G1 Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
100000453151827596110135169217
--------31.1164.5260.78-8.5428.0014.5822.7325.1928.40
7,500.00-----166.6793.5592.1691.46100.0078.1368.1855.5644.3834.56
0000000294775000000
-7-21-34-64-85-122-99-148-147-47-22211112644
-200.0061.9088.2432.8143.53-18.8549.49-0.68-68.03-53.19-109.09450.00-136.3669.23
27.4127.4127.4118.233.3237.537.8841.9443.6351.73000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The G1 Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the G1 Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2014201520162017201820192020202120222023
                   
3.722.947.3103.8369.3269.2207.3221.2145.182.16
0000000.25.711.112.69
0000000000
00000003.516.212.44
00.80.60.80.81.88.913.37.27.66
3.723.747.9104.6370.1271216.4243.7179.6114.95
0.10.10.30.51.113.410.5986.38
0000000000
0000000000
0000000000
0000000000
000000.41.71.50.50.21
0.10.10.30.51.113.812.210.58.56.59
3.823.848.2105.1371.2284.8228.6254.2188.1121.54
                   
14.153.4107.60000000.01
000222.5573.2592.4613.5728800.8815.37
-10.6-31.7-65-129.1-214.4-336.9-436.1-584.5-732-779.99
0000000000
0000000000
3.521.742.693.4358.8255.5177.4143.568.835.39
0.31.12.64.23.43.73.62.97.43.99
0.112.97.5916.117.524.326.723.17
00.10.20002.40.41.52.56
0000000000
0000000000
0.42.25.711.712.419.823.527.635.629.72
00000019.975.27751.56
0000000000
0000.10.19.57.97.86.64.88
0000.10.19.527.88383.656.44
0.42.25.711.812.529.351.3110.6119.286.15
3.923.948.3105.2371.3284.8228.7254.1188121.55
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of G1 Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand G1 Therapeutics's financial health and stability.

Assets

G1 Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that G1 Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of G1 Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into G1 Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
-6-20-30-60-85-122-99-148-147-47
0000000000
0000000000
003606-4-8-5-5
0526203237464428
0000001278
0000000000
-6-13-25-50-74-99-83-132-128-38
00000-20000
00000-200-502
00000000-502
0000000000
00000020550-26
633501083412292520
6334910734022114552-26
----1.00----1.00--
0000000000
0192456265-99-6113-126-62
-6.6-13.93-25.39-50.81-75.02-102.29-83.74-132.11-129.13-38.34
0000000000

G1 Therapeutics stock margins

The G1 Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of G1 Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for G1 Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the G1 Therapeutics's sales revenue. A higher gross margin percentage indicates that the G1 Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the G1 Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the G1 Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the G1 Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the G1 Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the G1 Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

G1 Therapeutics Margin History

G1 Therapeutics Gross marginG1 Therapeutics Profit marginG1 Therapeutics EBIT marginG1 Therapeutics Profit margin
2029e91.28 %33.36 %20.69 %
2028e91.28 %16.68 %15.55 %
2027e91.28 %3.64 %8.72 %
2026e91.28 %172 %10.71 %
2025e91.28 %-12.05 %2.93 %
2024e91.28 %-33.52 %-29.59 %
202391.28 %-47.91 %-58.13 %
202292.69 %-265.46 %-287.64 %
202193.58 %-452.54 %-471.25 %
202091.28 %-213.03 %-219.14 %
201991.28 %0 %0 %
201891.28 %0 %0 %
201791.28 %0 %0 %
201691.28 %0 %0 %
201591.28 %-2,965.38 %-4,171.15 %
201491.28 %-642.31 %-690.38 %

G1 Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The G1 Therapeutics earnings per share therefore indicates how much revenue G1 Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue G1 Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates G1 Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of G1 Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating G1 Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

G1 Therapeutics Revenue, EBIT and net profit per share

DateG1 Therapeutics Sales per ShareG1 Therapeutics EBIT per shareG1 Therapeutics Earnings per Share
2029e4.12 undefined0 undefined0.85 undefined
2028e3.21 undefined0 undefined0.5 undefined
2027e2.57 undefined0 undefined0.22 undefined
2026e2.1 undefined0 undefined0.22 undefined
2025e1.83 undefined0 undefined0.05 undefined
2024e1.42 undefined0 undefined-0.42 undefined
20231.59 undefined-0.76 undefined-0.93 undefined
20221.18 undefined-3.12 undefined-3.38 undefined
20210.75 undefined-3.4 undefined-3.54 undefined
20201.2 undefined-2.55 undefined-2.62 undefined
20190 undefined-3.44 undefined-3.27 undefined
20180 undefined-2.68 undefined-2.56 undefined
20170 undefined-3.35 undefined-3.56 undefined
20160 undefined-1.11 undefined-1.27 undefined
20150.02 undefined-0.56 undefined-0.79 undefined
20140.04 undefined-0.24 undefined-0.26 undefined

G1 Therapeutics business model

G1 Therapeutics Inc is a biopharmaceutical company that was founded in 2008 and is headquartered in Research Triangle Park, North Carolina, USA. The company specializes in the treatment of cancer and is dedicated to improving the quality of life for cancer patients. G1 Therapeutics is one of the most popular companies on Eulerpool.com.

G1 Therapeutics SWOT Analysis

Strengths

G1 Therapeutics Inc possesses several strengths that contribute to its success in the market:

  • Strong and experienced management team with deep knowledge of the pharmaceutical industry.
  • Robust pipeline of innovative oncology therapeutics, offering potential for high revenue growth.
  • Strong focus on research and development, enabling the company to stay at the forefront of scientific advancements.
  • Strong intellectual property portfolio, providing a competitive advantage and protecting against potential patent infringements.
  • Positive brand reputation and industry recognition for delivering groundbreaking cancer treatments.

Weaknesses

Despite its strengths, G1 Therapeutics Inc also faces certain weaknesses which may hinder its growth:

  • Reliance on a limited number of products in its pipeline, making the business susceptible to failures in clinical trials or regulatory issues.
  • Significant capital requirement for successful clinical trials and commercialization of new products, potentially straining financial resources.
  • Strong competition in the oncology therapeutics market from both established pharmaceutical companies and emerging biotech firms.
  • Limited geographic presence and market reach, currently focused primarily on the United States.

Opportunities

G1 Therapeutics Inc can capitalize on the following opportunities to drive its growth and expand its market presence:

  • Growing global demand for innovative cancer treatments, creating a favorable market environment for G1 Therapeutics Inc to introduce new products.
  • Potential partnerships and collaborations with larger pharmaceutical companies to leverage their resources, expertise, and distribution networks.
  • Expansion into international markets to reach a broader patient population and diversify revenue streams.
  • Increasing adoption of personalized medicine approaches, which aligns with G1 Therapeutics Inc's focus on developing targeted therapies.

Threats

G1 Therapeutics Inc should be aware of the following threats that could impact its business and industry performance:

  • Stringent regulatory requirements and potential delays in obtaining necessary approvals for new drugs.
  • Emergence of alternative treatment methods such as immunotherapies or gene therapies, which may disrupt the market for traditional oncology therapeutics.
  • Risk of clinical trial failures or adverse events, leading to loss of investor confidence and negative impact on the company's reputation.
  • Potential challenges in securing adequate reimbursement from healthcare insurers for newly developed treatments.

G1 Therapeutics Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

G1 Therapeutics Revenue by Segment

Segmente202320222021
Product sales, net46.34 M USD31.34 M USD-
License revenue36.17 M USD19.96 M USD-
License Revenue--20.36 M USD
Product Sales, Net--11.12 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

G1 Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

G1 Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

G1 Therapeutics shares outstanding

The number of shares was G1 Therapeutics in 2024 — This indicates how many shares 51.734 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue G1 Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates G1 Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of G1 Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating G1 Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for G1 Therapeutics.

G1 Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.17 -0.1  (40.58 %)2024 Q2
3/31/2024-0.21 -0.2  (4.63 %)2024 Q1
12/31/2023-0.28 -0.21  (25.19 %)2023 Q4
9/30/2023-0.34 -0.35  (-4.29 %)2023 Q3
6/30/2023-0.22 0.14  (162.75 %)2023 Q2
3/31/2023-0.65 -0.53  (18.81 %)2023 Q1
12/31/2022-0.86 -0.73  (15.21 %)2022 Q4
9/30/2022-0.64 -0.59  (8.51 %)2022 Q3
6/30/2022-1.04 -0.92  (11.46 %)2022 Q2
3/31/2022-0.99 -1.15  (-15.67 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the G1 Therapeutics stock

Eulerpool World ESG Rating (EESG©)

59/ 100

🌱 Environment

36

👫 Social

99

🏛️ Governance

43

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

G1 Therapeutics shareholders

%
Name
Stocks
Change
Date
7.99104 % Eshelman Ventures LLC4,216,074-300,0003/31/2024
5.59255 % MedImmune Ventures, Inc.2,950,63003/31/2024
2.48673 % Water Island Capital, LLC1,312,000-175,3829/30/2024
1.04246 % Eshelman (Fredric N)550,000300,0003/31/2024
0.38940 % Bailey (John E JR)205,44997,3387/5/2024
0.37028 % Muir (Glenn P)195,35810,0006/13/2024
0.24804 % Umstead (John W. V)130,86834,4737/5/2024
0.21986 % Velleca (Mark A.)116,00008/8/2023
0.20207 % Perry (Andrew)106,61433,6637/5/2024
0.12926 % Goldman Sachs Asset Management International68,19668,1966/30/2024
1
2
3
4
5
...
10

G1 Therapeutics Executives and Management Board

Mr. Andrew Perry

(50)
G1 Therapeutics Chief Commercial Officer
Compensation 3.13 M

Mr. John Bailey

(58)
G1 Therapeutics President, Chief Executive Officer, Director (since 2020)
Compensation 3.02 M

Mr. Terry Murdock

(62)
G1 Therapeutics Chief Operating Officer
Compensation 2.75 M

Dr. Rajesh Malik

(64)
G1 Therapeutics Chief Medical Officer
Compensation 1.5 M

Mr. Mark Avagliano

(47)
G1 Therapeutics Chief Business Officer
Compensation 1.14 M
1
2
3

G1 Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,540,340,390,59-0,30-0,52
Genor Biopharm Stock
Genor Biopharm
SupplierCustomer0,420,740,840,850,95
Merck Stock
Merck
SupplierCustomer0,310,470,540,68-0,09-0,47
EQRx Stock
EQRx
SupplierCustomer0,130,25-0,450,390,80
Pfizer Stock
Pfizer
SupplierCustomer-0,340,48-0,200,33-0,76-0,69
1

Most common questions regarding G1 Therapeutics

What values and corporate philosophy does G1 Therapeutics represent?

G1 Therapeutics Inc represents values of innovation, dedication, and patient-centered care. Their corporate philosophy revolves around the development of novel therapies to address the unmet needs of patients with cancer. As a biopharmaceutical company, G1 Therapeutics is committed to improving outcomes and quality of life for individuals battling cancer. Their focus on precision medicine and understanding the biology of cancer has led to the creation of potential breakthrough therapies. G1 Therapeutics Inc strives to make a positive impact in the lives of patients worldwide by relentlessly pursuing innovative approaches to cancer treatment.

In which countries and regions is G1 Therapeutics primarily present?

G1 Therapeutics Inc is primarily present in the United States.

What significant milestones has the company G1 Therapeutics achieved?

G1 Therapeutics Inc, a renowned biopharmaceutical company, has achieved several significant milestones. One notable accomplishment is the FDA approval of their key drug, trilaciclib, as a treatment for small cell lung cancer (SCLC). Additionally, G1 Therapeutics Inc successfully completed a Phase 2 clinical trial demonstrating positive results for trilaciclib in patients with metastatic triple-negative breast cancer (mTNBC). The company also entered into partnerships with leading organizations, such as Boehringer Ingelheim, for the global development and commercialization of their investigational oral selective estrogen receptor degrader (SERD) in breast cancer. These achievements solidify G1 Therapeutics Inc as a promising player in the field of oncology therapeutics.

What is the history and background of the company G1 Therapeutics?

G1 Therapeutics Inc is a pharmaceutical company specializing in the development of novel therapies for patients with cancer. Founded in 2008, G1 Therapeutics is focused on advancing their pipeline of small molecule therapies that target key pathways involved in cell cycle progression and DNA damage repair. The company has garnered attention for its innovative approach to cancer treatment, utilizing precision medicine and targeted therapies. G1 Therapeutics' dedication to improving the lives of cancer patients has propelled its growth and success in the biopharmaceutical industry. With a strong focus on clinical development and strategic partnerships, G1 Therapeutics continues to pave the way for advancements in oncology therapeutics.

Who are the main competitors of G1 Therapeutics in the market?

The main competitors of G1 Therapeutics Inc in the market include pharmaceutical companies such as Bristol-Myers Squibb, Merck & Co., and Pfizer Inc.

In which industries is G1 Therapeutics primarily active?

G1 Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of G1 Therapeutics?

The business model of G1 Therapeutics Inc focuses on the development and commercialization of novel therapies for the treatment of cancer. The company aims to address the unmet needs of patients by advancing its pipeline of potential therapies that target specific cellular pathways involved in tumor growth. G1 Therapeutics Inc leverages its expertise in cell cycle biology and deep understanding of cancer biology to develop innovative drugs, with a particular focus on targeting metastatic breast cancer and small cell lung cancer. Through strategic partnerships and collaborations, G1 Therapeutics Inc aims to bring its potential breakthrough therapies to market, improving the lives of cancer patients worldwide.

What is the P/E ratio of G1 Therapeutics 2025?

The G1 Therapeutics P/E ratio is 130.92.

What is the P/S ratio of G1 Therapeutics 2025?

The G1 Therapeutics P/S ratio is 3.84.

What is the Quality Investing of G1 Therapeutics?

The Quality Investing for G1 Therapeutics is 2/10.

What is the revenue of G1 Therapeutics 2025?

The expected G1 Therapeutics revenue is 96.38 M USD.

How high is the profit of G1 Therapeutics 2025?

The expected G1 Therapeutics profit is 2.83 M USD.

What is the business model of G1 Therapeutics

G1 Therapeutics is a biopharmaceutical company specializing in the development of groundbreaking cancer drugs to improve the lives of patients suffering from various forms of cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics' business model is based on the development and marketing of drugs targeting specific target proteins found in cancer cells. By targeting these proteins, the company effectively inhibits the proliferation and spread of cancer cells. In addition, the company also provides services in the areas of research and development and clinical trials to ensure that the effectiveness and safety of its drugs are of the highest level. The company has developed several product lines targeting different types of cancer. Primarily, this includes innovative therapeutics for the treatment of advanced stage cancers, particularly advanced lung cancer and breast cancer. The company's flagship product is Rintodestrant (G1T48), an orally administered selective estrogen receptor modulator (SERM) currently being investigated in phase 2b clinical trials for the treatment of ER-positive (ER+) breast cancer. Rintodestrant offers an alternative treatment profile for patients receiving anti-hormone therapies, improving their quality of life by minimizing undesirable effects such as hot flashes, bleeding, and cardiovascular diseases. The company has also developed a drug candidate called Trilaciclib (G1T28), which is used as the first and only myelosuppression-reducing drug to protect bone marrow associated with chemotherapy. Trilaciclib should be used in situations where significant myelosuppressive chemotherapy is anticipated. Alongside chemotherapy, it may help reduce the toxic effects on bone marrow function, especially hematopoietic stem cells. With the introduction of additional monoclonal antibodies and immunotherapy variants, the company aims to expand its presence in the field of cancer treatment and expand its portfolio of drugs manufactured on an improved medical basis. In addition to its own product development, G1 Therapeutics works closely with partners in the science and industry sectors to expand its knowledge and capabilities in the field of cancer research and development. Overall, G1 Therapeutics pursues an innovative business model and positions itself as a key partner in cancer research and development. Through the constant development of new drugs and services, the company contributes to improving healthcare and ensuring that patients can be effectively treated against cancer.

What is the G1 Therapeutics dividend?

G1 Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does G1 Therapeutics pay dividends?

The dividend cannot currently be calculated for G1 Therapeutics or the company does not pay out a dividend.

What is the G1 Therapeutics ISIN?

The ISIN of G1 Therapeutics is US3621LQ1099.

What is the G1 Therapeutics WKN?

The WKN of G1 Therapeutics is A2DR0J.

What is the G1 Therapeutics ticker?

The ticker of G1 Therapeutics is GTHX.

How much dividend does G1 Therapeutics pay?

Over the past 12 months, G1 Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, G1 Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of G1 Therapeutics?

The current dividend yield of G1 Therapeutics is .

When does G1 Therapeutics pay dividends?

G1 Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of G1 Therapeutics?

G1 Therapeutics paid dividends every year for the past 0 years.

What is the dividend of G1 Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is G1 Therapeutics located?

G1 Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von G1 Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of G1 Therapeutics from 3/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/6/2025.

When did G1 Therapeutics pay the last dividend?

The last dividend was paid out on 3/6/2025.

What was the dividend of G1 Therapeutics in the year 2024?

In the year 2024, G1 Therapeutics distributed 0 USD as dividends.

In which currency does G1 Therapeutics pay out the dividend?

The dividends of G1 Therapeutics are distributed in USD.

All fundamentals about G1 Therapeutics

Our stock analysis for G1 Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of G1 Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.